All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-02-10.
From the record
Enanta Pharmaceuticals, Inc.'s filings since 2017 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2022-02-10) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-3.3% a year over 10 filed years; profitable in 4 of 10.
From the record
Enanta Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $88 million in fiscal 2016 to $65 million in fiscal 2025, down 3.3% a year; it rose in 2 of 9 years; the deepest fall was 68% from fiscal 2018 to fiscal 2025; net income was positive in 4 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Enanta Pharmaceuticals, Inc.'s shareholder treatment is put at 8.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 18% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -127%: lost 127¢ per shareholder dollar. Leverage 77%: owes 77¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Enanta Pharmaceuticals, Inc. lost about 127 cents for every dollar of shareholders' money. Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count grew 0.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 315 in its family; net margin -125.4%.
From the record
Enanta Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $65 million in fiscal 2025 ranks in the top 41% by size; a net margin of -125.4% ranks in the top 48%; revenue growth of -8.8% a year over the last 3 filed years ranks in the bottom 27% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 30% of 315 in its family for leadership; chief executive since 2013.
From the record
Enanta Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Luly, Jay R. (President and CEO, as filed), filing under that title since 2013-03-20, 13.7 years (top 8% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 38%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 273 in its family for room to expand.
From the record
Enanta Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $32 million against no long-term debt tagged leaves 11.5% of its assets as net cash, bottom 29% of its family; cash from operations less capital spending is -49.2% of revenue (top 44%); research spending of 163.4% of revenue (top 44%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 48% of 306 in its family for growth drivers.
From the record
Enanta Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -8.8% a year over the last three filed years against -3.3% over all 10, slowing (bottom 43% of its family); the newest year grew -3.4% (bottom 33%); research spending grew -13.4% a year (bottom 26%); capital spending grew 82.4% a year (top 10%) (its annual reports). Enanta Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 38% of 233 in its family for expectations against reality.
From the record
Enanta Pharmaceuticals, Inc.'s newest year against its own record: revenue of $65 million in fiscal 2025 came in 9% above the $60 million its prior three years' pace pointed to (top 34% of its family); net income of $82 million against a prior three-year average of $124 million (top 40%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 39%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made